Skip to main content

NCI at ASCO Virtual Annual Meeting 2020

The National Cancer Institute (NCI) will be participating in the American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting to be held May 29-31.

NCI experts are taking part in more than on demand 80 presentations, including the clinical symposium and oral presentations listed below. Be sure to visit the ASCO Meeting Library for more information on these presentations and more.

Registration for the ASCO Virtual Meeting will remain open throughout the duration of the meeting. Registration includes access to the Virtual Scientific Program May 29 - 31 and the Virtual Education Program August 8 - 10. Registration is free for ASCO members. Register now.

Subscribe to stay updated on the latest abstracts, presentations, and resources from NCI at ASCO20 and future meetings.

Watch Dr. Sharpless Speak About Cancer Care in the Time of COVID

NCI Director Dr. Norman E. Sharpless

Credit: National Cancer Institute

NCI Director Dr. Norman E. Sharpless will participate in the panel discussion “Cancer Care in the time of COVID: Assessing Impact and Future Directions” on Saturday, May 30 at 4:30 p.m. ET. Details coming soon.

Virtual Meeting: NCI COVID-19 in Cancer Patients Study

NCI recently launched a national, longitudinal study of COVID-19 in people with cancer. The study, named NCI COVID-19 in Cancer Patients Study (NCCAPS), will help scientists answer key questions about COVID-19’s impact on cancer patients, as well as cancer’s impact on the course of COVID-19. The study aims to enroll 2,000 patients at more than 1,000 sites across the United States – with NCI encouraging any and all NCI-funded clinical trial sites to participate, especially sites reaching minority, underserved, and rural populations and sites with a high incidence of COVID-19.

NCI invites ASCO20 attendees to participate in a virtual presentation where study coordinators will review the objectives of NCCAPS and explain how you can participate in this important study. Look for your invite in the ASCO Virtual Meeting Platform. 

For more information about NCCAPS, check out the recent Cancer Currents blog post, “How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find Out

    Oral Presentations and Clinical Symposiums Featuring NCI Staff

    Abstract NCI Participant(s)
    Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.
    • Christian Hinrichs 
    • Scott Norberg 
    • Nisha Nagarsheth
    • Andrew Sinkoe
    • Thomas Meyer 
    • Jennifer Ann Kanakry 
    • Nikolaos Gkitsas 
    ALTERNATE:  Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
    • Larissa Korde
    Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F
    • Lisa McShane 
    • Larry V Rubinstein 
    • Mickey Williams 
    • Lyndsay Harris 
    • Alice P. Chen 
    • Keith Flaherty 
    • David R Patton 
    Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma.
    • W Marston Linehan 
    • Ramaprasad Srinivasan 
    Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.
    • Ramaprasad Srinivasan 
    • Sandeep Gurram 
    • Munjid Al Harthy 
    • Abhinav Sidana 
    • Mark Wayne Ball 
    • Julia C. Friend 
    • Lisa Mac 
    • Erin Purcell 
    • Cathy Vocke 
    • Peter L Choyke 
    • Lori Long
    • Joanna Shih 
    • Maria J Merino 
    • W. Marston Linehan 
    A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
    • Elise C Kohn
    Underdiagnosis and undertreament of modifiable cardiovascular risk factors: A Childhood Cancer Survivor Study (CCSS) report.
    • Todd M Gibson
    Neuroleptic rotation for refractory agitation in cancer patients with delirium in the acute palliative care unit: A double-blind randomized clinical trial.
    • Terri Armstrong

    COVID-19 and Guidance for Clinical Trials

    NCI is working with doctors and health care staff who carry out clinical trials to implement specific measures that will address the current challenges of providing care to patients during the COVID-19 pandemic. Consult your Institutional Review Board for potential measures to protect participants and research staff. A comprehensive list of COVID-related resources from NCI is available at Coronavirus: Guidance for Cancer Researchers.

    For additional information and guidance, check out the following from articles and blog posts from Dr. Norman E. Sharpless; Dr. Dinah Singer, NCI Deputy Director; and Dr. Oliver Bogler, Director of the NCI Center for Cancer Training.

    NCI-ComboMATCH Clinical Trial

    Submit a letter of intent by 5:00 p.m. ET on June 30, 2020.

    NCI’s National Clinical Trials Network is developing a successor precision medicine trial to `NCI-Molecular Analysis for Therapy Choice (NCI-MATCH)' entitled `NCI-ComboMATCH'. The principal of this initiative is to overcome drug resistance to single-agent therapy by developing genomically-directed targeted agent combinations. We invite applications from Clinical Laboratory Improvements Program (CLIA) certified/accredited laboratories that test tumor specimens from patients utilizing Next-Generation Sequencing (NGS) assays to participate in the NCI-ComboMATCH trial.

    Funding Opportunities Available

    • Posted:

    If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “NCI at ASCO Virtual Annual Meeting 2020 was originally published by the National Cancer Institute.”